Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Publication year range
1.
Eur J Paediatr Neurol ; 21(6): 807-815, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28803159

ABSTRACT

Telangiectasias are prominent small vessels (venules, capillaries or arterioles) that are visible as small red-purple focal lesions in the skin and mucous membranes. They can serve as a cutaneous marker for a number of primary (mostly hereditary) disorders and they can be secondary to other (systemic) diseases. Patients with telangiectasias are seen by general health practitioners, pediatricians, (pediatric) neurologists, dermatologists, and ophthalmologists. In this article we give an overview of the different disorders in which telangiectasias are a prominent feature, focusing on neurocutaneous disorders in which they serve as a marker for establishing the right diagnosis. The pattern of distribution of the telangiectasias, their age of onset and associated features are helpful to distinguish between the different disorders.


Subject(s)
Telangiectasis/etiology , Telangiectasis/pathology , Female , Humans , Telangiectasis/diagnosis
2.
Eur J Paediatr Neurol ; 20(5): 723-31, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27321953

ABSTRACT

Complex paediatric neurology (CPN) patients generally present with non-specific symptoms, such as developmental delay, impaired movement and epilepsy. The diagnostic trajectory in these disorders is usually complicated and long-lasting, and may be burdensome to the patients and their parents. Additionally, as caring for a chronically ill child can be stressful and demanding, parents of these patients may experience impaired health-related quality of life (HRQoL). This study aims to assess parental HRQoL and factors related to it in CPN. Physical and mental HRQoL of 120 parents was measured and compared to the general population using the SF-12 questionnaire. Parents also completed this questionnaire for the measurement of patient HRQoL. Additional questionnaires were used to measure parental uncertainty (Visual Analogue Scale) and worry phenomena (Penn State Worry Questionnaire), and to obtain socio-demographic data. A linear mixed model with random effect was used to investigate which of these variables were associated with parental HRQoL. As compared to the general population, HRQoL of these parents appeared diminished. Fathers showed both lowered physical (51.76, p < 0.05) and mental (49.41, p < 0.01) HRQoL, whereas mothers only showed diminished mental (46.46, p < 0.01) HRQoL. Patient HRQoL and parental worry phenomena were significantly correlated with overall and mental parental HRQoL. The reduction in parental mental HRQoL is alarming, also because children strongly rely on their parents and parental mental health is known to influence children's health. Awareness of these problems among clinicians, and supportive care if needed are important to prevent exacerbation of the problems.


Subject(s)
Caregivers/psychology , Developmental Disabilities/psychology , Parents/psychology , Quality of Life/psychology , Adult , Child , Chronic Disease/psychology , Female , Humans , Male , Middle Aged , Surveys and Questionnaires
3.
Eur J Paediatr Neurol ; 19(2): 233-9, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25604808

ABSTRACT

BACKGROUND: The diagnostic trajectory of complex paediatric neurology may be long, burdensome, and expensive while its diagnostic yield is frequently modest. Improvement in this trajectory is desirable and might be achieved by innovations such as whole exome sequencing. In order to explore the consequences of implementing them, it is important to map the current pathway. To that end, this study assessed the healthcare resource use and associated costs in this diagnostic trajectory in the Netherlands. METHODS: Fifty patients presenting with complex paediatric neurological disorders of a suspected genetic origin were included between September 2011 and March 2012. Data on their healthcare resource utilization were collected from the hospital medical charts. Unit prices were obtained from the Dutch Healthcare Authority, the Dutch Healthcare Insurance Board, and the financial administration of the hospital. Bootstrap simulations were performed to determine mean quantities and costs. RESULTS: The mean duration of the diagnostic trajectory was 40 months. A diagnosis was established in 6% of the patients. On average, patients made 16 physician visits, underwent four imaging and two neurophysiologic tests, and had eight genetic and 16 other tests. Mean bootstrapped costs per patient amounted to €12,475, of which 43% was for genetic tests (€5,321) and 25% for hospital visits (€3,112). CONCLUSION: Currently, the diagnostic trajectories of paediatric patients who have complex neurological disease with a strong suspected genetic component are lengthy, resource-intensive, and low-yield. The data from this study provide a backdrop against which the introduction of novel techniques such as whole exome sequencing should be evaluated.


Subject(s)
Nervous System Diseases/diagnosis , Nervous System Diseases/economics , Neurologic Examination/economics , Neurology/economics , Pediatrics/economics , Adolescent , Age Factors , Child , Child, Preschool , Costs and Cost Analysis , Exome/genetics , Female , Genetic Testing/economics , Health Resources/economics , Health Resources/statistics & numerical data , Hospitalization/economics , Humans , Infant , Infant, Newborn , Male , National Health Programs/economics , Nervous System Diseases/genetics , Netherlands , Sequence Analysis, DNA , Treatment Outcome
4.
Eur J Paediatr Neurol ; 18(3): 243-8, 2014 May.
Article in English | MEDLINE | ID: mdl-24120489

ABSTRACT

Alpha-fetoprotein (AFP) is present in fetal serum in concentrations up to 5,000,000 µg/l. After birth, AFP gene expression is turned down with a subsequent fall of the serum concentrations of this albumin-like protein to 'adult values' of circa 0.5-15 µg/l from the age of 2 years onwards. Irrespective of its assumed important functions, individuals with AFP deficiency appear fully healthy. The other way around, the presence of AFP in the circulation after the first years of life doesn't seem to harm, since individuals with 'hereditary persistence of AFP' are also without clinical abnormalities. During pregnancy, AFP (in maternal serum) has long been recognized as a marker for congenital anomalies of the fetus. Equally well known is AFP as biomarker for hepatocellular carcinoma and some other malignancies. There are at least four neurodegenerative disorders, all inherited as autosomal recessive traits and characterized by the presence of cerebellar ataxia, abnormal ocular movements, and neuropathy, for which an elevated concentration of serum AFP is an important diagnostic biomarker. The availability of a reliable biomarker is not only important during screening or diagnostic processes, but is also relevant for objective follow-up during (future) therapeutic interventions.


Subject(s)
Ataxia/diagnosis , Biomarkers/metabolism , Neurodegenerative Diseases/diagnosis , alpha-Fetoproteins/metabolism , Animals , Ataxia/genetics , Ataxia/metabolism , Female , Humans , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/metabolism , Phenotype , Pregnancy , alpha-Fetoproteins/genetics
5.
Ned Tijdschr Geneeskd ; 152(43): 2313-6, 2008 Oct 25.
Article in Dutch | MEDLINE | ID: mdl-19024058

ABSTRACT

In 3 young male patients, aged 10, 19 and 21 years respectively, sequential, severe, painless bilateral visual loss occurred. Ophthalmological examination revealed no other abnormalities and this delayed the diagnosis Leber's hereditary optic neuropathy (LHON). LHON is a mitochondrial genetic disease characterised by bilateral acute or subacute painless loss of central vision. LHON causes blindness, predominantly in young adult males but less frequently in women and children as well. Occasionally, LHON is associated with other neurological and cardiac changes. The first patient recovered his vision within 2 years, but the other 2 remained blind. All 3 patients had a m.11778G > A mutation in the mitochondrial DNA (mtDNA). Over 95% of LHON cases are primarily the result of one of three mitochondrial DNA point mutations. In addition, analysis of patients grouped according to mtDNA mutation has demonstrated differences in both the clinical features of visual failure and in recurrence risks for relatives that are associated with each of the pathogenic mtDNA mutations. Depending on the type of mutation, recovery of vision occurs in 4-58% of the patients. Whilst pathogenic mtDNA mutations are required for the development of LHON, other factors must be responsible for the variable penetrance and male predominance. Familiarity with the clinical spectrum of LHON is necessary for early diagnosis. There is no proven treatment.


Subject(s)
Blindness/etiology , DNA, Mitochondrial/genetics , Optic Atrophy, Hereditary, Leber/diagnosis , Blindness/genetics , Child , Diagnosis, Differential , Humans , Male , Mutation , Optic Atrophy, Hereditary, Leber/complications , Optic Atrophy, Hereditary, Leber/genetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL